Commodore Capital’s Ocular Therapeutix OCUL Stock Holding History

Commodore Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,575,000	Closed	-$21.8M	–	38
2026 Q1	$21.8M	Buy	+2,575,000	New	+$24.5M	1.26%	24

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commodore Capital's OCUL Position: Q2 2026 in Review

Commodore Capital sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 2,575,000 shares — an estimated $21.8M sold.

Commodore Capital first reported a position in OCUL in Q1 2026 and held it in 1 quarter. The position peaked at $21.8M in Q1 2026. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Commodore Capital reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
Commodore Capital sold 2,575,000 Ocular Therapeutix shares in Q2 2026, an estimated $21.8M.
Commodore Capital first reported a position in Ocular Therapeutix in Q1 2026 and held it in 1 quarter.
Commodore Capital's Ocular Therapeutix position peaked at $21.8M in Q1 2026.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.